Revumenib
Nov 21, 2024•15 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
The 1st menin inhibitor, revumenib, is approved for relapsed/refractory acute leukemias.
Understanding the Pathway: https://doi.org/10.1200/JCO-24-01265
For the best experience, listen in Metacast app for iOS or Android